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Abstract
Introduction Despite the substantial prevalence of gout in the
ageing female population, female hormonal influence has not
been comprehensively examined. We evaluated and quantified
the potential independent association between menopause,
postmenopausal hormone use and serum uric acid levels in a
nationally representative sample of women.
Methods Using data from 7662 women aged 20 years and
older in the Third National Health and Nutrition Examination
Survey (1988 to 1994), we examined the relation between
menopause, postmenopausal hormone use and serum uric acid
levels. We used multivariate linear regression to adjust for other
risk factors for hyperuricaemia such as dietary factors, age,
adiposity, alcohol use, renal function, hypertension and diuretic
use.
Results Menopause was associated with higher serum uric acid
levels. After adjusting for covariates, serum uric acid levels
among women with natural menopause and surgical
menopause were greater than premenopausal women by 0.34
mg/dl (95% confidence interval [CI], 0.19 to 0.49) and 0.36 mg/
dl (95% CI, 0.14 to 0.57), respectively. Current
postmenopausal hormone use was associated with a lower
serum uric acid level among postmenopausal women
(multivariate difference, 0.24 mg/dl [95% CI, 0.11 to 0.36]). The
serum uric acid levels increased with increasing age categories
(crude difference between 20 to 29 years and 70 years and over
= 1.03 mg/dl, p for trend < 0.001), but this increase was not
present after adjusting for other covariates (p for trend = 0.66).
Conclusions These findings from a nationally representative
sample of US women indicate that menopause is independently
associated with higher serum uric acid levels, whereas
postmenopausal hormone use is associated with lower uric acid
levels among postmenopausal women. The age-associated
increase in serum uric acid levels in women may be explained by
menopause and other age-related factors.
Introduction
Despite the doubling of the incidence of gout among women
over the past 20 years [1] and the substantial prevalence par-
ticularly in the ageing female population [2], little is known
about the risk factors for gout and hyperuricaemia specifically
among women. Given the important gender differences in the
frequency of gout and serum uric acid levels, the risk factors
for gout may vary between genders. A central factor behind
these differences is thought to be female hormonal influence,
but its magnitude has not been comprehensively examined
and quantified. Thus, it is unknown if menopause is associated
with serum uric acid levels independent of age and other cov-
ariates and if so, by what magnitude. Conversely, postmeno-
pausal hormone use may be independently associated with
lower serum uric acid levels, but no nationally representative
information is available. Furthermore, previous studies
reported an age-dependent increase in serum uric acid levels
among women [3-5], but it is unknown if this increase is inde-
pendent of menopausal effect or other age-related factors. To
study these issues, we examined a nationally representative
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sample of women (the US Third National Health and Nutri-
tional Examination Survey [NHANES III]) [6,7].
Materials and methods
Study population
Conducted between 1988 and 1994, the NHANES III
included a representative sample of the non-institutionalised
civilian US population, which was selected by using a multi-
stage, stratified sampling design [6]. After a home interview,
participants were invited to attend examination sessions
where blood and urine specimens were obtained. For partici-
pants unable to attend the examination sessions for health rea-
sons, a blood sample was obtained during the home interview.
Our analysis was limited to women aged 20 years or older who
attended the medical examination: of these women 7662 had
complete information. We repeated our analyses among 7531
participants after excluding those who self-reported gout or
were taking allopurinol or uricosuric agents (n = 131).
The NHANES III underwent institutional review board approval
and written informed consent was obtained from participants.
Uric acid measurement
Serum uric acid was measured by oxidisation with the specific
enzyme uricase to form allantoin and hydrogen peroxide
(Hitachi Model 737 Multichannel Analyzer, Boehringer Man-
nheim Diagnostics, Indianapolis, IN). Details about quality-con-
trol procedures have been published elsewhere [7]. Values
are reported in milligrams per decilitre; to convert to micro-
moles per litre, multiply by 59.48.
Assessment of menopausal status and postmenopausal 
hormone use
Participants were categorised as premenopausal (ovarian
function intact), surgically menopausal (both ovaries removed
surgically before cessation of menses) or naturally menopau-
sal (nonsurgical loss of ovarian function) [8]. Participants with
no history of reproductive surgery were classified as premen-
opausal if they reported having had a menstrual period during
the previous 12 months and postmenopausal if they did not,
consistent with World Health Organization criteria [8].
Women who had undergone a hysterectomy (without ovariec-
tomy) that coincided with the date of the last menstrual period
were assigned a menopausal classification on the basis of age
(< 51 years were premenopausal; ≥ 51 years were naturally
menopausal) [8]. Women with no history of hysterectomy or
ovariectomy who were current users of hormone replacement
therapy were classified in the same way. Women who had
undergone bilateral ovariectomy that coincided with the date
of the last menstrual period were classified as surgically men-
opausal [8]. Women who had undergone hysterectomy or ova-
riectomy after the date of the last menstrual period were
classified as naturally menopausal. The amount of time since
menopause was estimated as the difference in years between
age at the time of the NHANES interview and self-reported
age at the time of the last menstrual period or ovariectomy,
whichever came first.
Women were classified as current users, past users or never
users of postmenopausal hormone use on the basis of self-
reported data from the examination questionnaire [8]. Duration
of postmenopausal hormone use in years was also ascer-
tained by self-report at the time of the examination.
Assessment of covariates
The average daily intakes of total meat, seafood, dairy foods,
sugar-sweetened soft drinks and coffee were derived from
responses to a food frequency questionnaire. The food fre-
quency questionnaire assessment of dietary intake has been
shown to be a valid and reliable method of assessing average
dietary consumption [9,10]. The NHANES III collected infor-
mation on body measurements (including height and weight),
medication use (including diuretics, anti-hypertensives, allopu-
rinol and uricosuric agents), medical conditions (including self-
reported physician-diagnosed diabetes, hypertension and
gout) and serum creatinine levels. Glomerular filtration rate
(GFR) was estimated by using the simplified Modification of
Diet in Renal Disease study equation: GFR (ml/min/1.73 m2)
= 186 × (serum creatinine level [mg/dl])-1.154 × (age)-0.203 ×
[0.742, if female] × [1.212, if black] [11-13]. Body mass index
was calculated by dividing the weight in kilograms by the
square of the height in metres.
Statistical analysis
All statistical analyses were computed using survey com-
mands of STATA (eg, SVYMEAN and SVYREG (StataCorp
LP Texas)) to incorporate sample weights and adjust for clus-
ters and strata of the complex sampling design. We used lin-
ear regression modelling to evaluate the relation between
menopause, postmenopausal hormone use and serum uric
acid levels. These models were adjusted for age; smoking sta-
tus; body mass index; use of diuretics, beta-blockers, allopuri-
nol and uricosuric agents; self-reported hypertension; GFR;
and intake of total energy, total meats, seafood, dairy foods,
sugar-sweetened soft drinks and coffee. When categorical
analyses suggested linear trends across categories, statistical
significance of trends were assessed in the final multivariate
linear regression models using the median values of each cat-
egory to minimise the influence of outliers.
We explored potential interactions by body mass index (< 25
kg/m2 vs ≥ 25 kg/m2), hypertension (yes vs no) and alcohol
use (abstainer vs drinker) by testing the significance of inter-
action terms added to our final multivariate models. For all dif-
ference estimates and odds ratios (OR), we calculated 95%
confidence intervals (CI). All P values are two-sided.
Results
The population's mean age was 46 years. The mean serum
uric acid level was 4.64 mg/dl. The characteristics of the studyAvailable online http://arthritis-research.com/content/10/5/R116
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population according to menopausal status are shown in
Table 1. Postmenopausal women were older, more often
hypertensive and more likely to use diuretics and uric acid-low-
ering medication than premenopausal women. These differ-
ences were larger when compared with natural menopause
than surgical menopause. Postmenopausal women tended to
consume less sweetened soft drinks, but more coffee than
premenopausal women.
Menopause was associated with a higher serum uric acid
level. Unadjusted serum uric acid levels among women with
natural menopause and surgical menopause were higher than
among premenopausal women by 0.80 mg/dl (95% CI, 0.70
to 0.89) and 0.68 mg/dl (95% CI, 0.48 to 0.87), respectively
(Table 2). After adjusting for age and other covariates, the dif-
ferences were attenuated to 0.34 mg/dl in women with natural
menopause and 0.36 mg/dl in women with surgical meno-
pause, but remained significant (Table 2). When we excluded
from the analysis participants who self-reported gout or were
taking allopurinol or uricosuric agents (n = 131), the corre-
sponding differences were 0.34 mg/dl in women with natural
menopause and 0.37 mg/dl in women with surgical meno-
pause (both p values ≤ 0.001). The independent association
with menopause did not vary significantly among subgroups
by body mass index (< 25 kg/m2 vs ≥ 25 kg/m2), hypertension
(yes vs no) and alcohol use (abstainer vs drinker) (p values for
interaction > 0.3). Among women who had experienced natu-
ral menopause and had never used postmenopausal hor-
mones, serum uric acid levels were higher in those who were
younger than 40 years at menopause than in women who were
60 years or older at menopause (multivariate difference 0.50
mg/dl, [95% CI, 0.09 to 0.90]).
Among postmenopausal women, current users of postmeno-
pausal hormones tended to be younger and less often hyper-
tensive than past or never users of postmenopausal hormones
(Table 3). Past users of postmenopausal hormones reported
using urate-lowering medication less frequently.
Current postmenopausal hormone use was associated with a
lower serum uric acid level among postmenopausal women.
Unadjusted serum uric acid levels associated with current
postmenopausal hormone use were lower than in women who
had never used postmenopausal hormones by 0.44 mg/dl
(95% CI, 0.30 to 0.58) (Table 4). After adjusting for age and
other covariates, the difference was attenuated to 0.24 mg/dl,
but remained significant (Table 4). When we excluded from
our analysis participants who self-reported gout or were taking
allopurinol or uricosuric agents (n = 117), the multivariate dif-
ferences were 0.26 mg/dl (95% CI, 0.12 to 0.39) for current
postmenopausal hormone use and 0.15 mg/dl (95% CI, 0.01
to 0.28) for past postmenopausal hormone use. The inde-
pendent association with postmenopausal hormone use did
not vary significantly among subgroups by body mass index (<
25 kg/m2 vs ≥ 25 kg/m2), hypertension (yes vs no) and alcohol
use (abstainer vs drinker) (p values for interaction > 0.06).
Compared with no postmenopausal hormone use, the multi-
variate differences in serum uric acid levels were -0.38 mg/dl
for duration of current postmenopausal hormone use of less
than one year, -0.37 mg/dl for one to five years of use and -
Table 1
Characteristics of women in the NHANES III according to menopausal status
Variable Premenopausal Natural menopause Surgical menopause All participants
Participants, n 4156 3047 459 7662
Age (years) 34 63 58 46
Body mass index (kg/m2)2 6 2 7 2 7 2 6
Diuretic use (%) 2 18 15 8
Hypertension (%) 14 43 37 25
Alcohol intake (servings/day) 0.2 0.2 0.1 0.2
Total meat intake (servings/day) 1.0 0.9 0.9 1.0
Seafood intake (servings/day) 0.2 0.2 0.2 0.2
Dairy food intake (servings/day) 1.5 1.4 1.4 1.4
Sweetened soft drink intake (servings/day) 0.5 0.2 0.3 0.4
Coffee intake (servings/day) 0.9 1.3 1.1 1.0
Uric acid drug usea (%) 0.0 1.3 0.5 0.5
Creatinine (mg/dl) 0.9 1.0 1.0 1.0
Data are presented incorporating sample weights and adjusted for clusters and strata of the complex sample design of NHANES III. aAllopurinol 
and uricosuric agents.Arthritis Research & Therapy    Vol 10 No 5    Hak and Choi 
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0.16 mg/dl (95% CI, -0.29 to -0.03) for more than five years of
postmenopausal hormone use. The corresponding multivari-
ate differences for duration of past postmenopausal hormone
use were -0.14 mg/dl, 0.02 mg/dl and -0.28 mg/dl (95% CI, -
0.52 to -0.04).
Serum uric acid levels did not vary significantly up to the age
category of 40 to 49 years, but increased thereafter with
increasing age categories (p for trend < 0.001) (Table 5). The
unadjusted difference between 20 and 29 years of age and 70
years of age or older was 1.03 mg/dl. This increase in older
age categories was attenuated after adjusting for menopausal
status, but remained significant (p for trend < 0.001). How-
ever, when we additionally adjusted for GFR in the model, the
association was no longer present (p for trend = 0.19). Instead
of adjusting for GFR, when we additionally adjusted for creat-
inine levels, diuretic use and hypertension, the association was
again not present (p for trend = 0.25). There was no significant
trend in multivariate models adjusting for other covariates (p
for trends > 0.53) (Table 5).
Discussion
In this nationally representative sample of US women, we
found that both natural and surgical menopause were associ-
ated with increased serum uric acid levels. The magnitude of
associations was slightly larger than that associated with one
daily serving of liquor (0.29 mg/dl), which was estimated
based on NHANES III data [14]. In comparison, current post-
Table 2
Differences in serum uric acid levels (mg/dl) among women according to menopausal statusa
Menopausal status Premenopausal Natural menopause Surgical menopause
Participants, n 4156 3047 459
Unadjusted difference (95% CI) 0 (referent) 0.80 (0.70 to 0.89) 0.68 (0.48 to 0.87)
Age-adjusted difference (95% CI) 0 (referent) 0.43 (0.28 to 0.58) 0.37 (0.17 to 0.57)
Multivariate differenceb (95% CI) 0 (referent) 0.33 (0.18 to 0.48) 0.34 (0.12 to 0.55)
Multivariate differencec (95% CI) 0 (referent) 0.34 (0.19 to 0.49) 0.36 (0.14 to 0.57)
aUric acid levels are reported in milligrams per decilitre (mg/dl); to convert to μm/l, multiply by 59.48. Data are presented incorporating sample 
weights and adjusted for clusters and strata of the complex sample design of NHANES III. bAdjusted for age, smoking status, body mass index, 
use of postmenopausal hormone, diuretics, beta-blockers, allopurinol and uricosuric agents, hypertension and glomerular filtration rate. 
cAdditionally adjusted for intake of alcohol, total meats, seafood, dairy foods, sugar-sweetened soft drinks, coffee and total energy. CI, confidence 
interval.
Table 3
Characteristics of postmenopausal women in the NHANES III according to postmenopausal hormone use
Variable Never Past use Current
Participants, n 2446 607 453
Age (years) 64 63 56
Body mass index (kg/m2)2 8 2 7 2 6
Diuretic use (%) 18 18 16
Hypertension (%) 43 48 34
Alcohol intake (servings/day) 0.1 0.1 0.2
Total meat intake (servings/day) 0.9 0.9 0.9
Seafood intake (servings/day) 0.2 0.2 0.2
Dairy food intake (servings/day) 1.4 1.5 1.3
Sweetened soft drink intake (servings/day) 0.3 0.2 0.2
Coffee intake (servings/day) 1.2 1.2 1.3
Uric acid drug usea (%) 1.4 0.4 1.4
Creatinine (mg/dl) 1.0 1.0 1.0
Data are presented incorporating sample weights and adjusted for clusters and strata of the complex sample design of NHANES III. aAllopurinol 
and uricosuric agents.Available online http://arthritis-research.com/content/10/5/R116
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menopausal hormone use was associated with lower uric acid
levels among postmenopausal women. These associations
were independent of other risk factors for hyperuricaemia such
as age, body mass index, dietary risk factors, alcohol intake,
renal function, hypertension and diuretic use. We also found a
substantial increase in serum uric acid levels among women
aged 50 years or older, but this increase was not present after
adjusting for menopause and other age-related factors. These
findings suggest that the increase was explained by meno-
pause and other age-related factors that are associated with
hyperuricaemia.
A biological mechanism that has been postulated to underlie
the relation between menopause, postmenopausal hormone
replacement use and serum uric acid levels is the impact of
oestrogens on the renal tubular handling of uric acid [15-17].
Premenopausal levels of oestrogens in women may promote
more efficient renal clearance of urate [15-17]. Serum urate
concentrations in men average about 1 mg/dl higher than in
women in adult life, but the serum uric acid levels in women
increase substantially around the age of natural menopause,
as shown in current and previous findings [3,4,15,18,19]. Fur-
thermore, administration of oestrogen therapy to males was
shown to decrease serum uric acid levels [17]. In parallel with
our results, among women enrolled in the Heart and Estrogen-
Progestin replacement Study, treatment with postmenopausal
hormones resulted in a serum uric acid level of 0.2 mg/dl lower
than placebo at one year of follow-up [20]. We observed no
increasing hypouricaemic benefits with increasing duration of
current postmenopausal hormone use of more than one year,
although there were some increasing trends with past post-
menopausal hormone use. Potential explanations for this
include a survival effect, confounding of unmeasured covari-
ates and a threshold effect of menopause on serum uric acid
levels.
Table 4
Differences in serum uric acid levels (mg/dl) among postmenopausal women according to postmenopausal hormone usea
Postmenopausal hormone use Never Past use Current
Participants, n 2464 607 453
Unadjusted difference (95% CI) 0 (referent) -0.10 (-0.28 to 0.08) -0.44 (-0.58 to -0.30)
Age-adjusted difference (95% CI) 0 (referent) -0.09 (-0.26 to 0.09) -0.34 (-0.49 to -0.18)
Multivariate differenceb (95% CI) 0 (referent) -0.13 (-0.27 to 0.01) -0.24 (-0.36 to -0.12)
Multivariate differencec (95% CI) 0 (referent) -0.13 (-0.27 to 0.02) -0.24 (-0.36 to -0.11)
aUric acid levels are reported in milligrams per decilitre (mg/dl); to convert to μm/l, multiply by 59.48. Data are presented incorporating sample 
weights and adjusted for clusters and strata of the complex sample design of NHANES III. bAdjusted for age, sex, smoking status, body mass 
index, use of diuretics, beta-blockers, allopurinol and uricosuric agents, hypertension and glomerular filtration rate. cAdditionally adjusted for intake 
of alcohol, total meats, seafood, dairy foods, sugar-sweetened soft drinks, coffee and total energy. CI, confidence interval.
Table 5
Differences in serum uric acid levels (mg/dl) among women according to age categoriesa
Age category 
(years)
20 to 29 30 to 39 40 to 49 50 to 59 60 to 69 ≥ 70 P value for 
trend
Participants, n 1627 1637 1203 904 987 1304 -
Unadjusted 
difference (95% CI)
0 (referent) 0.20 (-0.12 to 
0.16)
0.12 (-0.04 to 
0.28)
0.60 (0.44 to 
0.75)
0.84 (0.69 to 
1.00)
1.03 (0.90 to 
1.16)
< 0.001
Menopause-adjusted 
difference (95% CI)
0 (referent) 0.00 (-0.14 to 
0.14)
0.02 (-0.14 to 
0.18)
0.27 (0.10 to 
0.44)
0.45 (0.23 to 
0.67)
0.62 (0.43 to 
0.81)
< 0.001
Menopause-GFR 
Adjusted difference 
(95% CI)
0 (referent) -0.09 (-0.25 to -
0.08)
-0.13 (-0.35 to -
0.10)
0.07 (-0.18 to 
0.32)
0.17 (-0.18 to 
0.52)
0.27 (-0.10 to 
0.64)
0.19
Multivariate 
differenceb (95% CI)
0 (referent) -0.23 (-0.37 to -
0.08)
-0.33 (-0.53 to -
0.14)
-0.22 (-0.44 to 
0.00)
-0.16 (-0.46 to 
0.14)
-0.06 (-0.39 to 
0.27)
0.54
Multivariate 
differencec (95% CI)
0 (referent) -0.22 (-0.37 to -
0.08)
-0.34 (-0.53 to -
0.16)
-0.22 (-0.45 to 
0.00)
-0.15 (-0.45 to 
0.14)
-0.03 (-0.36 to 
0.30)
0.66
aUric acid levels are reported in milligrams per decilitre (mg/dl); to convert to μm/l, multiply by 59.48. Data are presented incorporating sample 
weights and adjusted for clusters and strata of the complex sample design of NHANES III. bAdjusted for age, smoking status, body mass index, 
use of postmenopausal hormone, diuretics, beta-blockers, allopurinol and uricosuric agents, hypertension and glomerular filtration rate. 
cAdditionally adjusted for intake of alcohol, total meats, seafood, dairy foods, sugar-sweetened soft drinks, coffee and total energy. CI, confidence 
interval.Arthritis Research & Therapy    Vol 10 No 5    Hak and Choi 
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Age-related increases in serum uric acid levels among women
have been reported by previous cross-sectional studies [3-5].
In contrast, serum urate levels did not vary significantly among
men [3-5]. A study based on 3013 female residents of Tecum-
seh, MI [5] and a study based on 254 women in the UK [3]
reported a rise in serum urate levels after age 50 to 54 years
with a subsequent plateau. Another study based on 18,324
Japanese females reported increasing uric acid levels up to
the age of 70 years or over [4]. Given the coinciding time peri-
ods, investigators inferred that this observation may be due to
hormonal changes accompanying the menopause. Further-
more, previous case series found that the vast majority of
female gout cases were diagnosed after menopause
[15,18,19,21]. We found that serum uric acid levels among
women increased from age 50 to 59 onwards and the
increase extended up to the highest age category of 70 years
of age and older. The increase attenuated substantially after
adjusting for menopausal status, but remained significant, sug-
gesting that menopause explains a substantial portion, but not
all, of the age-associated increase among women. The remain-
ing age-associated increase was explained by other age-
related factors such as renal function, diuretic use and hyper-
tension. Whether these factors also affect the risk of gout
more strongly among women than among men remains to be
examined in prospective studies with gout as the outcome.
Strengths and limitations of our study deserve comment. This
study was performed in a nationally representative sample of
US women; thus, the findings are likely to be generally appli-
cable to US women. Although previous reports and biological
plausibility suggest that female hormone use would affect the
serum uric acid levels [15-17,20] as observed, a cross-sec-
tional study design tends to leave uncertainty regarding the
temporal sequence of exposure-outcome relations. Thus, con-
firming the relation between menopause, postmenopausal
hormone use and incident hyperuricaemia or gout in a pro-
spective longitudinal context would be valuable. Furthermore,
it would be interesting to prospectively study if increasing
serum uric acid trends associated with age translate into an
increased risk of gout and, if so, if the trends can be explained
by age-associated hyperuricaemic factors.
Conclusion
In conclusion, our findings from a nationally representative
sample of US women indicate that menopause is independ-
ently associated with higher serum uric acid levels, whereas
postmenopausal hormone use is associated with lower uric
acid levels among postmenopausal women. The age-depend-
ent increase in serum uric acid levels in women may be
explained by menopause and other age-associated factors.
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